AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aquestive Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.83+0.05 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $478.73M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.25 (−45.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aquestive Therapeutics, Inc. grew revenue 22.6% to $54.09M over the twelve months to Jun 30, 2026. Free cash flow was -$45.95M.
Revenue
$54.09M
+22.6% vs. a year earlier
Operating income
-$52.75M
TTM Q2 2026
Free cash flow
-$45.95M
TTM Q2 2026
EPS, diluted
-$0.65
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $478.73M
- P/E ratio
- –
- Price to sales
- 8.85
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -9.60%
Fundamentals
- Revenue
- $54.09M
- Net income
- -$78.23M
- EPS, diluted
- -$0.65
- Free cash flow
- -$45.95M
- Book value per share
- -$0.45
- Diluted shares
- 125M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$54.09M+22.6% YoY
Gross profit
$36.26M+34.5% YoY
Operating income
-$52.75M
Net income
-$78.23M
EPS, diluted
-$0.65
Free cash flow
-$45.95M
Reported periodTrailing twelve months